Treatment of nmCRPC
Description
In this short video, Professor Amit Bahl reflects on the evolution of the non-metastatic castration resistant prostate cancer (nmCRPC) treatment landscape with the advent of second-generation androgen receptor inhibitors (ARIs) in nmCRPC and presents the key outcomes from the three clinical trials; ARAMIS, PROSPER and SPARTAN.1,2,3 Professor Bahl also discusses the criteria for identifying these high-risk patients for referral and treatment.
Professor. Amit Bahl
Professor Bahl is a Consultant Clinical Oncologist at Bristol Cancer Institute, University Hospitals Bristol. He is an Executive Committee member of the British Uro-oncology Group. He has been an expert adviser to NICE for the technology appraisal on new treatments in prostate and renal cancer. Professor Bahl is actively involved in research into breast, prostate, bladder, renal and penile cancers and has more than 100 publications in these research areas, as well as several presentations at national and international meetings.
Learn more about NUBEQA here
Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc Tel: 01182063500, Fax: 01182063703, Email: pvuk@bayer.com.
If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc Email: qualitycomplaints@bayer.com For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.
